Comparing Injectable DaxibotulinumtoxinA and OnabotulinumtoxinA in Moderate and Severe Glabellar Lines: Additional...

Area of Science:

• Neurology
• Dermatology
• Aesthetics

Background:

• DaxibotulinumtoxinA (RT002) is an investigational botulinum toxin Type A.
• Phase 2 data indicate 40U daxibotulinumtoxinA offers greater response rates and longer duration (median 24 weeks) than 20U onabotulinumtoxinA, with a favorable safety profile.

Purpose of the Study:

• To assess if baseline glabellar line severity influences the efficacy and safety of daxibotulinumtoxinA.
• To compare daxibotulinumtoxinA with onabotulinumtoxinA across different severity levels of glabellar lines.

Main Methods:

• A Phase 2, randomized, double-blind, multicenter study.
• Participants with moderate or severe glabellar lines received 20U, 40U, or 60U daxibotulinumtoxinA, 20U onabotulinumtoxinA, or placebo.
• Investigator-assessed efficacy was monitored for at least 24 weeks.

Main Results:

• Analysis of the per-protocol population (n=191) stratified by baseline severity (125 moderate, 66 severe).
• The clinical advantage of 40U daxibotulinumtoxinA over 20U onabotulinumtoxinA was maintained across various efficacy outcomes in both moderate and severe glabellar lines.
• Statistical evaluations were limited by subgroup size.

Conclusions:

• 40U daxibotulinumtoxinA demonstrates a clinical efficacy advantage over 20U onabotulinumtoxinA for both moderate and severe glabellar lines.
• A greater advantage was observed in patients with severe glabellar lines.